Lacosamide APIs from Loncom Pharma offer a new frontier in seizure management. As a functionalized amino acid, its mode of action involves enhancing the slow inactivation of voltage-gated sodium channels, leading to stabilization of hyperexcitable neuronal membranes. These APIs are a testament to Loncom Pharma's commitment to innovation in the neurological field, providing a vital component for medications that offer a better therapeutic profile for patients with epilepsy.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
